Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 广州市香雪制药股份有限公司是一家生产销售现代中药及医疗设备等的医药企业.公司主要产品有"香雪"抗病毒口服液和板蓝根颗粒等.2006年以来,香雪商标相继被评为"广州市著名商标"、"广东省著名商标"、"中国驰名商标".2009年4月,香雪制药与第16届亚运会组委签订协议,成为"广州2010年亚运会药品供应商".公司石杉碱甲贴片是国内首创的治疗抗老年痴呆的新药,被列为国家"十五"重大科技专项"创新药物和中药现代化"课题(863计划).快速医用胶508系列产品是目前全球唯一在临床应用的α-氰基丙烯酸高纯度高碳烷基酯医用胶.公司还荣获"2003年度中国制药行业企业信用AAA级单位","2009年度广东省医药工业中成药制造、中药饮片加工20强企业"、"2009年度广东省医药工业综合实力50强企业"等众多名誉。
Main Business 现代中药的生产与销售，辅之医疗设备等业务。
Legal Representative 王永辉
Top Executives
董事长：王永辉
董事：徐力,谭文辉
独立董事：周庆权,吴杰,陶剑虹
Top 5 Shareholder
Shareholder name Nature Holding Date
广州市昆仑投资有限公司流通A股22.59%30/09/2024
广州市罗岗自来水有限公司流通A股4.06%30/09/2024
MORGANSTANLEY&CO.INTERNATIONAL PLC.流通A股0.60%30/09/2024
BARCLAYS BANK PLC流通A股0.46%30/09/2024
中国国际金融股份有限公司流通A股0.46%30/09/2024
Company Secretary 徐力
Solicitors 广东正平天成律师事务所
Auditors 立信会计师事务所（特殊普通合伙）
Tel No 020-22211007;020-22211010
Fax No 020-22211018
Website www.xphcn.com
Email directorate@xphcn.com;huangbl@xphcn.comxul@xphcn.com
Company Address
Register: 广东省广州市黄埔区科学城金峰园路2号
Office: 广东省广州市黄埔区广州开发区科学城金峰园路2号（自编第一、二、三、四、五、六、七、八栋）
Listing Date 15/12/2010
Shares Capital
Shares Capital: 661,279,045
Total A Share: 661,279,045
Listed A Share: 657,459,042
Non-tradable A Share: 3,820,003
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ -0.590
DPS(RMB)* --
NBV Per Share(RMB)* ¥ 2.911
Market Capitalization(RMB) 8.120B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.